Our lead product, leronlimab (PRO 140), is a subcutaneous injection for HIV that prevents healthy cells from viral entry.
Read More on LeronlimabRecent research demonstrates the potential importance of the CCR5 receptor as a therapeutic target in oncology.
Read More on CCR5Stay informed and receive company updates straight to your inbox.